Invasive fungal infection
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Cases where different preparations of amphotericin B (AmB, ABCD, L-AmB) were used continuously for more than three days; 2. Cases of invasive fungal infections with clinical diagnoses (such as Cryptococcus, Aspergillus, Mucor, Malnefi, etc.); 3. For special groups (such as those with malignant blood diseases, hematopoietic stem cell transplantation, or solid organ transplantation), corresponding host factors (such as neutrophil deficiency for =10 days, having received allogeneic hematopoietic stem cell transplantation, long-term history of glucocorticoid or immunosuppressant use, etc.) must be present.
Exclusion criteria
Exclusion criteria: 1. Incomplete data or missing key information (such as lack of laboratory tests, medication records, follow-up outcomes, etc.); 2. Amphotericin B was used for less than 3 days or was interrupted during the treatment period; 3. Death or irreversible renal function impairment caused by other reasons (such as severe bacterial infection, surgical complications, etc.) that cannot be attributed to amphotericin B; 4. Patients who do not meet the requirements of host factors (such as no neutrophil deficiency, no immunosuppressive therapy, etc.) do not fall within the definition of high-risk groups for invasive fungal infections.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Site of infection;Amphotericin B dosage and administration regimen;Duration of treatment;Concomitant antimicrobial agents used;Clinical response (cure, improvement, no change, failure);Microbiological outcome (eradication, presumed eradication, replacement, reinfection, persistence); | — |
Countries
China
Contacts
The first affiliated hostipal of nanchang university